Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports

Merck is reportedly nearing a roughly $6 billion all-cash deal to acquire Terns Pharma, with negotiations said to be in advanced stages and an agreement possible within days. The acquisition supports Merck's reshaping of its oncology strategy around Keytruda ahead of its 2028 patent expiry; Terns, focused on chronic myeloid leukemia, jumped ~10% in after-hours trading. Merck and Terns did not immediately comment.

Analysis

Large-cap pharmas are increasingly buying narrow hematology/oncology assets to accelerate combination strategies rather than to replace near-term top-line — that changes how the market should value late-stage hematology targets. Instead of pure single-agent peak-sales valuation, acquirers price in combination synergies and exclusivity value; that compresses standalone exit valuations for small-cap developers while increasing option value for assets that plug into broad immuno-oncology platforms.

Second-order winners include specialists in late-stage CMC, assay development, and clinical trial delivery (CDMOs/CROs) where bolt-on programs ramp manufacturing and trial activity quickly; expect 3–12 month demand upticks for fill/finish and bioanalytical services tied to integration timetables. Conversely, small single-indication biotechs that lack easy combo partners face a higher probability of down-round financing or being shopped at distressed multiples in 6–18 months.

Key near-term catalysts are deal confirmation, financing disclosure, and the acquirer’s integration plan for combination trials — each can re-rate either the buyer or target within days to weeks. Mid-term (6–24 months) readouts on combination safety/efficacy and milestone payments determine ultimate ROI; the biggest tail risk is a strategic pivot away from bolt-on combos, which would leave acquired assets underutilized and valuations impaired.

Consensus is under-adjusting for balance-sheet opportunity cost and buyback impact when large buyers deploy cash on bolt-ons; that can cap multiple expansion for the acquirer even if pipeline breadth improves. Markets often overpay for perceived “near-term oncology upside” — creating asymmetric alpha for disciplined event-driven arbitrage and for trades that isolate combo-synergy optionality from single-agent clinical risk.

Key Decisions for Investors

• Initiate a small core position in Merck (MRK): buy 1–2% NAV outright on any confirmed deal close or on a >3% post-announcement dip; horizon 6–12 months. Risk/reward: asymmetric if combination plans validate (target +12–18%), downside -12–20% if integration disappoints — size to limit single-deal execution risk.
• Merger-arb conditional long Terns Pharmaceuticals (TERN): enter only after a definitive agreement is filed; size <=4% NAV and monitor financing/termination clauses. Expected IRR modest (low single-digits over days–weeks) while tail-risk (deal break) is binary — hedge with out-of-the-money puts on the acquirer if available to cap downside.
• Buy CDMO/CRO exposure: initiate CTLT (Catalent) 3% NAV or ICLR (ICON) 3% NAV for a 6–12 month trade to capture incremental demand from integration-driven manufacturing and trials. Target +20–30% upside if deal activity continues; downside -20% in a broad clinical slowdown — use trailing stops or small covered-call overlays to improve carry.
• Relative-value defensive pair (optional): long a diversified oncology incumbent such as BMY (Bristol-Myers Squibb) 2% NAV and short a small single-asset hematology microcap basket (aggregate 2% NAV) for 6–12 months. Rationale: incumbents capture combo optionality with lower binary risk; shorts capture increased financing/default risk among single-asset developers — aim for 1.5:1 potential reward:risk.